Cancer drug and antidepressants provide clues for treating brain-eating amoeba infections

September 13, 2018, University of California - San Diego
Cancer drug and antidepressants provide clues for treating brain-eating amoeba infections
N. fowleri growth is inhibited with a combination treatment of breast cancer drug tamoxifen and epiminolanosterol (left) as compared to the untreated amoebae (right). Credit: UC San Diego Health

The amoeba Naegleria fowleri is commonly found in warm swimming pools, lakes and rivers. On rare occasions, the amoeba can infect a healthy person and cause severe primary amebic meningoencephalitis, a "brain-eating" disease that is almost always fatal. Other than trial-and-error with general antifungal medications, there are no treatments for the infection.

Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego have now identified three new molecular targets in N. fowleri and a number of drugs that are able to inhibit the amoeba's growth in a laboratory dish. Several of these drugs are already approved by the U.S. Food and Drug Administration for other uses, such as antifungal agents, the breast cancer drug tamoxifen and antidepressant Prozac.

Their findings are published September 13 in PLoS Pathogens.

"Not many drugs can cross the blood-brain barrier," said senior author Larissa Podust, Ph.D., associate professor at Skaggs School of Pharmacy. "Even if a drug can inhibit or kill the amoeba in a dish, it will not work in a host animal if it does not make it into the brain. That's why we started with drugs known for their brain effects." Podust led the study with co-first authors Anjan Debnath, Ph.D., assistant professor at Skaggs School of Pharmacy, and Wenxu Zhou, Ph.D., of Texas Tech University.

Podust and team began by investigating N. fowleri's sterol biosynthesis pathway—a series of enzymes that build the 's outer membrane. They inhibited three of these enzymes to see how it would affect the organism's viability. The researchers found that all three enzymes might make good drug targets. One of these, a sterol isomerase, is similar to a human receptor known to play a role in human neurological conditions, such as addiction, amnesia, pain and depression.

The researchers then tested a number of drugs already known to inhibit these enzymes for their ability to inhibit N. fowleri growth in the lab. All 13 of the new drugs they tested were more potent than miltefosine, an investigational drug currently recommended by the U.S. Centers for Disease Control and Prevention (CDC) for the treatment of primary amebic meningoencephalitis, in combination with other medications.

For example, while it takes 54.5 micromolar (μM) of miltefosine to arrest the growth of half the amoebae growing in a dish, it only took 5.8 μM of tamoxifen and 31.8 μM of Prozac. Tamoxifen and Prozac inhibit two different enzymes in N. fowleri's sterol biosynthesis pathway. When the researchers combined a lower dose of tamoxifen with drugs that inhibit other enzymes in the sterol biosynthesis pathway, they were able to inhibit the growth of 95 percent of N. fowleri. In other words, combination treatment allowed them to inhibit more of the pathogen using lower drug concentrations.

"Drug repurposing is a relevant strategy for this infection because there is little economic incentive for the pharmaceutical industry to develop new drugs to treat these rare diseases," Debnath said. "Already-approved drugs can also lessen the time and expense required to develop a drug from the laboratory to the clinic."

According to the CDC, only four of 143 people known to be infected with N. fowleri in the U.S. from 1962 to 2017 have survived. However, the number of the university laboratories conducting research on N. fowleri is few, partly due to a liability for laboratory safety risks. The Center for Discovery and Innovation in Parasitic Diseases at Skaggs School of Pharmacy and Pharmaceutical Sciences at UC San Diego is home to just one of six university-based laboratories worldwide conducting drug discovery research on live N. fowleri, and, based on current publications, the only university in the U.S. with a mouse model of the infection.

Explore further: Compounds in desert creosote bush could treat giardia and 'brain-eating' amoeba infections

More information: PLoS Pathogens (2018). DOI: 10.1371/journal.ppat.1007245

Related Stories

Compounds in desert creosote bush could treat giardia and 'brain-eating' amoeba infections

August 15, 2017
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego and the University of Colorado Anschutz Medical Campus have found that compounds produced by the creosote bush, a ...

CDC frees up drug that fights brain-eating amoeba

August 22, 2013
(HealthDay)—Miltefosine, a potentially life-saving experimental drug to treat people infected with a rare but deadly brain-eating amoeba, is now available to U.S. doctors directly from the U.S. Centers for Disease Control ...

Use sterile or boiled water for nasal washing abroad to avoid amoeba infection

January 27, 2015
The Norwegian Institute of Public Health has been informed that a woman from Oslo died in December 2014 after returning from Thailand where she had been infected with the Naegleria fowleri amoeba. The source of infection ...

Special drug rushed to help brain-eating amoeba patient (Update)

August 3, 2016
A pharmaceutical company has rushed a special drug that once saved the life of a girl who contracted a usually deadly brain-eating amoeba to a South Carolina hospital with its own patient fighting the disease.

Climate change may be pushing 'Brain-eating' amoeba to northern lakes

July 25, 2015
(HealthDay)—A deadly "brain-eating" amoeba that lives in freshwater sources may be surviving in more northern areas of the United States thanks to climate change, health experts suggest.

Florida boy fights rare infection caused by amoeba (Update)

August 13, 2013
Health officials in Florida say a 12-year-old boy is fighting a rare and deadly infection that is attacking his brain.

Recommended for you

Antibiotic prescribing influenced by team dynamics within hospitals

November 15, 2018
Antibiotic prescribing by doctors is influenced by team dynamics and cultures within hospitals.

Discovery suggests new route to fight infection, disease

November 14, 2018
New research reveals how a single protein interferes with the immune system when exposed to the bacterium that causes Legionnaires' disease, findings that could have broad implications for development of medicines to fight ...

Zika may hijack mother-fetus immunity route

November 14, 2018
To cross the placenta, Zika virus may hijack the route by which acquired immunity is transferred from mother to fetus, new research suggests.

Maternally acquired Zika immunity can increase dengue disease severity in mouse pups

November 14, 2018
To say that the immune system is complex is an understatement: an immune response protective in one context can turn deadly over time, as evidenced by numerous epidemiological studies on dengue infection, spanning multiple ...

New research aims to help improve uptake of hepatitis C testing

November 14, 2018
New research published in Scientific Reports shows persisting fears about HIV infection may impact testing uptake for the hepatitis C Virus (HCV).

Synthetic DNA-delivered antibodies protect against Ebola in preclinical studies

November 13, 2018
Scientists at The Wistar Institute and collaborators have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models. Study results, published ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.